Giving a major boost to the claims of plaintiffs in the Xarelto Lawsuit Cases, two new types of research have come forward which will aid their case against Bayer and Janssen Pharmaceuticals. Before the unveiling of these researches, the plaintiffs had alleged that using rivaroxaban exposed them to risks of stomach bleeding, gastrointestinal problems, and vitreous hemorrhages.
They didn’t have any conclusive piece of evidence to support their claims. However, thanks to these studies which have been carried out by two independent bodies, a comparison has been drawn between the use of the Novel Oral Anticoagulant (NOAC) and a risks of accruing harmful diseases.
Consequently, these studies will inevitably add pressure on the Bayer and Janssen Pharmaceuticals – the manufacturers of Xarelto. So far, both these organizations denied any wrongdoing on the basis that they didn’t have any previous knowledge of the harmful effects of their drug.
However, once these studies will be presented in the court, they will substantiate the claims of the plaintiffs in which they alleged that the manufacturers deliberately hid information to sell their drug. More importantly, these studies will also deal a major blow to the sales of the dangerous blood thinner which have been skyrocketing in the past few years.
Despite its legal battle in the court, the sales of Xarelto in the U.S. market have refused to slow down. For example, in the first quarter of 2016, the sales of Bayer – parent company of the drug, are up by 12.2 percent.
More importantly, the sales of the blood thinner surged by 31.5 percent in the first quarter. This increase in the drug’s consumption was mainly observed in China and Japan, where huge volume increases were noted. As for the U.S. market, Bayer stated that the business of their drug “developed positively”.
Thus, in the light of the above-mentioned financial figures, the upcoming researches could prove to be detrimental in the profits of Bayer and Janssen Pharmaceutical.
Research # 1: Risk of Vitreous Hemorrhages
Led by a team of Doctors including Dr. John C and Dr. Judy Hun, this investigation was carried out on patients who are in the age bracket of 70-89. These patients have been using blood-thinning medicines for long and reported no problems before the usage of Xarelto.
Before the drug was approved by the Federal Drug Authority, almost all of these patients were using traditional blood thinning medicines. After the approval, they switched to rivaroxaban due to its “one dose fits all” appeal.
For example, if you are using any other blood thinning medicine, you would have to undergo blood tests before getting a prescription from the doctor about the dosage of the medicine. However, once you have switched to new oral anticoagulant, no such tests are required.
Talking about the research and the empirical results could have damning consequences for Xarelto. In one such result, patients who used it showed a clear surge in incidents relating to vitreous hemorrhages. More importantly, these incidents increased in number after these patients had used the drug for some months.
The team of doctors noted that almost all of these incidents happened in patients who had previously used other blood thinning drugs i.e. warfarin. However, as one might expect, this would not absolve rivaroxaban of the blame.
This research was made public when the doctors decided to publish it in the June 2015 issue of the JAMA Opthalmology journal.
Research # 2: Risk of Stomach bleeding
Another study which was carried out last year on Xarelto was published in the April 2015 issue of the British Medical Journal. In this study, more than 45,000 patients were investigated to learn about the outcome of using Xarelto. Looking at the scale of this investigation, it is easy to assume that this study will carry more weight in front of the jury in the courtroom.
Switching to the results of this study and they are equally disastrous for the dangerous blood thinner. In the result developing phase, the team of doctors screened more than 45,000 medical histories of patients. After compiling all those histories, the doctors came to a conclusion that, for patients who switched to Xarelto from warfarin, they are two-times more likely to contract stomach bleeding.
The research also shows that the bleeding incidents were most common in patients who had a history of taking warfarin.
Combination of Lawsuits
In the United States alone, the Judicial Panel on Multidistrict litigation decided to consolidate more than 2800 cases which were filed against Xarelto, into an MDL 2592. These case will be presented in the Eastern District of Louisiana under the tutelage of Judge Eldon Fallon.